Event

TNO’s attendance at the International Liver Congress 2017

RAI, Amsterdam, The Netherlands • 19 Apr 2017 - 23 Apr 2017

MANY WAYS ONE AIM: BEATING LIVER DISEASE

The International Liver CongressTM is the annual EASL meeting. Every year in April, scientific and medical experts from a broad range of fields, including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest updates and innovations in liver research.

Specialists share recent data, present studies and findings, and discuss the hottest topics on liver disease. The annual Congress attracts over 10,000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity!

TNO will present two posters of recent research topics. The first presentation, poster no. 343, entails that the CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. Obese patients with chronic inflammation in white adipose tissue (WAT) have an increased risk of developing non-alcoholic steatohepatitis (NASH). The C-C chemokine receptor-2 (CCR2) has a crucial role in the recruitment of immune cells to WAT and liver, thereby promoting the inflammatory component of the disease. We examined whether intervention with propagermanium, an inhibitor of CCR2, would attenuate tissue inflammation and NASH development in a mouse model.

Poster no. 344 focusses on the systems biology approach to identify processes and early markers for fibrosis in metabolically-induced non-alcoholic steatosis hepatitis in mice. The first part of the poster presentation focusses on identification of processes and pathways involved in the onset and progression of NASH and fibrosis over time with specific emphasis on early detection of fibrosis. The second parts shows the effect of pharmacological interventions on these early markers and their long-term effect on disease development.

Meet us on Saturday 22nd April at the poster area to learn more about these two fascinating topics and our research on NASH and fibrosis.

Our work

Preclinical NASH models

Nonalcoholic steatohepatitis (NASH) is one of the most prevalent chronic liver diseases. The number of patients suffering from NASH is increasing dramatically and is associated with metabolic syndrome,... Read more

We use anonymous cookies to enhance the use of our site.